In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes

Genes Chromosomes and Cancer

Volumn 53, Issue 7, 2014, Pages 549-557

  Tian, Erming ^a   Sawyer, Jeffrey R ^a   Heuck, Christoph J ^a   Zhang, Qing ^a   van Rhee, Frits ^a   Barlogie, Bart ^a   Epstein, Joshua ^a  

^a Myeloma Institute for Research and Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR MAFB;

ARTICLE; CANCER RISK; CCND1 GENE; CCND3 GENE; CHROMOSOME 14Q; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INTERPHASE; MMSET GENE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROMOTER REGION; CHROMOSOME 14; GENE FUSION; GENE TRANSLOCATION; GENETICS; METABOLISM;

CHROMOSOMES, HUMAN, PAIR 14; GENE EXPRESSION PROFILING; GENE FUSION; HUMANS; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

EID: 84899900966     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22165     Document Type: Article

References (30)

1. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R. 1999. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24:9-15.
2. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. 1996. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93:13931-13936.
3. Bergsagel PL, Kuehl WM. 2001. Chromosome translocations in multiple myeloma. Oncogene 20:5611-5622.
4. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, Peeters T, Michaux L, Hagemeijer A, Pearson PL, Clevers HC, Bast BJ. 2004. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: A molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 126:355-363.
5. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. 1998a. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025-3034.
6. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schröck E, Ried T, Kuehl WM. 1998b. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463.
7. Cogné M, Lansford R, Bottaro A, Zhang J, Gorman J, Young F, Cheng HL, Alt FW. 1994. A class switch control region at the 3′ end of the immunoglobulin heavy chain locus. Cell 77:737-747.
8. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. 2005. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Gene Chr Ca 44:194-203.
9. Dewald GW, Kyle RA, Hicks GA, Greipp PR. 1985. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390.
10. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD, Jr, Stewart AK, Avet-Loiseau H. 2004. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558.
11. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. 1988. Plasma cell karyotype in multiple myeloma. Blood 71:453-456.
12. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. 2004. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199.
13. Joy Ho P. Chromosomal and genetic abnormalities in myeloma. 2002. Clin Lab Haematol 24:259-269.
14. Kalff A, Spencer A. 2012. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies. Blood Cancer J 2:e89.
15. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B. 2012. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 97:622-630.
16. Kuehl WM, Bergsagel PL. 2002. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2:175-187.
17. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. 1995. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497.
18. Liang W, Hopper JE, Rowley JD. 1979. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders. Cancer 44:630-644.
19. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome. 2002. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:1579-1583.
20. Ross FM, Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT, Morgan GJ; UK Myeloma Forum. 2010. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95:1221-1225.
21. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J, Jr. 2003. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101:2374-2376.
22. Sawyer JR. 2011. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204:3-12.
23. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. 1998. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-194.
24. Seto M, Yamamoto K, Iida S, Akao Y, Utsumi KR, Kubonishi I, Miyoshi I, Ohtsuki T, Yawata Y, Namba M, et al. 1992. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 7:1401-1406.
25. Simon R. 2006. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J Natl Cancer Inst 98:1169-1171.
26. Taniwaki M, Nishida K, Ueda Y, Takashima T. 1996. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma 21:25-30.
27. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. 1995. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256.
28. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B. 1997. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 7:2659-2666.
29. Zaller DM, Eckhardt LA, 1985. Deletion of a B-cell-specific enhancer affects transfected, but not endogenous, immunoglobulin heavy-chain gene expression. Proc Natl Acad Sci USA 82:5088-5092.
30. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD, Jr. 2006. The molecular classification of multiple myeloma. Blood 108:2020-2028.